Hyperfine Inc. (Class A) (HYPR) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-01, Hyperfine Inc. (Class A) (NASDAQ: HYPR) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $0.74 (-5.23% 1D, market cap $78.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, HYPR ranks #485 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), HYPR carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of 49.8%, and ROIC of -35.0%. By comparison, OM (Outset Medical Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -28.0%, cap $78.8M) and ECOR (electroCore Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $73.1M). Among the 5-stock peer group, HYPR leads on earnings multiple (N/A) while OM leads on capital efficiency (-28.0% ROIC).
Per HYPR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001833769), Hyperfine Inc. (Class A) generated $13.6M in revenue (+5.2% YoY), -$35.6M in net income, and -$29.1M in free cash flow against $55.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 6/9
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While HYPR currently carries a cautious 45/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.81) and Max Pain ($0.78) forces dealer call-delta covering toward $2.04.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Hyperfine Inc. (Class A) (HYPR) dropped -5.23% to $0.74, trading at 3% of its 52-week range ($0.7 – $1.94). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Gainers Axogen (NASDAQ:AXGN) stock rose 17.7% to $44.1 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.1 billion. As per the news, the Q3 earnings report came out today.
Lucid Capital Markets analyst Alex Nowark initiates coverage on Hyperfine (NASDAQ:HYPR) with a Buy rating and announces Price Target of $2.
GUILFORD, Conn., October 22, 2026--CE mark and UKCA approvals support Swoop system Model 2 expansion as Hyperfine highlights portable MRI in brain health awareness efforts.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +5.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on HYPR today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for HYPR. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Hyperfine Inc. (Class A) (HYPR) ranks #485 by composite RQD confidence (45/100, grade D) and #691 by equity capitalization ($78.9M). Within this direct 5-issuer industry benchmark cohort, HYPR leads on earnings valuation at N/A trailing P/E, while OM leads on capital efficiency and profitability with -28.0% ROIC and 39.1% gross margin. HYPR currently leads its immediate peer cohort in composite quantitative strength at 45/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| HYPR
ACTIVE
Hyperfine Inc. (Class A) | D | 45/100 | — | 49.8% | -35.0% | -5.23% | $78.9M | Benchmark Subject |
| OM Outset Medical Inc. | D- | 35/100 | — | 39.1% | -28.0% | -3.46% | $78.8M | /om-vs-hypr → |
| ECOR electroCore Inc. | D- | 38/100 | — | 86.8% | -35.0% | -3.68% | $73.1M | /ecor-vs-hypr → |
| STXS Stereotaxis Inc. | E | 30/100 | — | 52.7% | -35.0% | -6.21% | $91.2M | /stxs-vs-hypr → |
| NRXS Neuraxis Inc. | E | 32/100 | — | 84.2% | -35.0% | -0.26% | $94.8M | /nrxs-vs-hypr → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Hyperfine Inc. (Class A) (HYPR) reported GAAP revenue of $13.6M (+5.2% vs. FY2024 revenue of $12.9M , and +22.9% cumulative change since FY2023) , GAAP net income of -$35.6M, operating cash flow of -$27.9M, and free cash flow of -$29.1M (+25.6% YoY). On the balance sheet, HYPR closed FY2025 with $55.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $13.6M | -$35.6M | -$27.9M | -$29.1M | $55.3M | $0 |
| FY2024 (FY) | 2024-12-31 | $12.9M | -$40.7M | -$38.8M | -$39.1M | $58.9M | — |
| FY2023 (FY) | 2023-12-31 | $11.0M | -$44.2M | -$41.8M | -$41.8M | — | — |
As of 2026-11-01, Hyperfine Inc. (Class A) (NASDAQ: HYPR) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $0.74 (-5.23% 1D, market cap $78.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, HYPR ranks #485 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), HYPR carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of 49.8%, and ROIC of -35.0%. By comparison, OM (Outset Medical Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -28.0%, cap $78.8M) and ECOR (electroCore Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $73.1M). Among the 5-stock peer group, HYPR leads on earnings multiple (N/A) while OM leads on capital efficiency (-28.0% ROIC).
Per HYPR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001833769), Hyperfine Inc. (Class A) generated $13.6M in revenue (+5.2% YoY), -$35.6M in net income, and -$29.1M in free cash flow against $55.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
HYPR last traded at $0.74 (-5.23% on volume of 680,381 shares), positioning the stock -8.64% below its 50-day simple moving average ($0.81) and -34.51% below its 200-day simple moving average ($1.13). Across its 52-week range of $0.70 to $1.94, HYPR sits at the 3.2% percentile with a 14-day RSI of 39.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.83).
Why HYPR Stock dropped -5.23% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).